Cholinesterase inhibitors in mild cognitive impairment: A meta-analysis of randomized controlled trials

Neurologia i Neurochirurgia Polska

Volumn 41, Issue 1, 2007, Pages 13-21

  Sobów, Tomasz ^a   Kłoszewska, Iwona ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cholinesterase inhibitors; Mild cognitive impairment; Placebo; Randomized controlled trials; Treatment

Indexed keywords

ALPHA TOCOPHEROL; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; DEMENTIA; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; MANTEL HAENSZEL TEST; META ANALYSIS; MORTALITY; NEUROPSYCHOLOGICAL TEST; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33847794764     PISSN: 00283843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Kral V.A. Senescent forgetfulness: benign and malignant. Can Med Assoc J 1962; 86: 257-260.
2. Petersen R.C., Smith G.E., Waring S.C., et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-308.
3. Winblad B., Palmer K., Kivipelto M., et al. Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256: 240-246.
4. Amieva H., Letenneur L., Dartigues J.F., et al. Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study. Dement Geriatr Cogn Disord 2004; 18: 87-93.
5. Morris J.C., Storandt M., Miller J.P., et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001; 58: 397-405.
6. Bennett D.A., Wilson R.S., Schneider J.A., et al. Natural history of mild cognitive impairment in older persons. Neurology 2002; 59: 198-205.
7. Hanninen T., Hallikainen M., Tuomainen S., et al. Prevalence of mild cognitive impairment: a population-based study in elderly subjects. Acta Neurol Scand 2002; 106: 148-154.
8. Kumar R., Dear K.B., Christensen H., et al. Prevalence of mild cognitive impairment in 60- to 64-year-old community-dwelling individuals: The Personality and Total Health through Life 60+ Study. Dement Geriatr Cogn Disord 2005; 19: 67-74.
9. Larrieu S., Letenneur L., Orgogozo J.M., et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 2002; 59: 1594-1599.
10. Hansson O., Zetterberg H., Buchhave P., et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study Lancet Neurol 2006; 5: 228-234.
11. Devanand D.P., Pelton G.H., Zamora D., et al. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Arch Neurol 2005; 62: 975-980.
12. Korf E.S., Wahlund L.O., Visser P.J., et al. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology 2004; 63: 94-100.
13. Arnaiz E., Almkvist O. Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease. Acta Neurol Scand Suppl 2003; 179: 34-41.
14. Ritchie C.W., Ames D., Clayton T., et al. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry 2004; 12: 358-369.
15. Takeda A., Loveman E., Clegg A., et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int J Geriatr Psychiatry 2006; 21: 17-28.
16. Price J.L., Morris J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999; 45: 358-368.
17. Bennett D.A., Schneider J.A., Bienias J.L., et al. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 2005; 64: 834-841.
18. Davis K.L., Mohs R.C., Marin D., et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999; 281: 1401-1406.
19. Gilmor M.L., Erickson J.D., Varoqui H., et al. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol 1999; 411: 693-704.
20. DeKosky S.T., Ikonomovic M.D., Styren S.D., et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002; 51: 145-155.
21. Ikonomovic M.D., Mufson E.J., Wuu J., et al. Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology. J Alzheimers Dis 2003; 5: 39-48.
22. Frolich L. The cholinergic pathology in Alzheimer's disease - discrepancies between clinical experience and pathophysiological findings. J Neural Transm 2002; 109: 1003-1013.
23. Koontz J., Baskys A. Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study. Am J Alzheimers Dis Other Demen 2005; 20: 295-302.
24. Salloway S., Ferris S., Kluger A., et al. Efficacy of donepezil in mild cognitive impairment. A randomized placebo-controlled trial. Neurology 2004; 63: 651-657.
25. CDR. Undertaking systematic reviews of research on effectiveness. Centre for Reviews and Dissemination, No4, York, UK. Accessible on-line: http://www.york.ac.uk/inst/crd/report4.htm
26. Petersen R.C., Thomas R.G., Grundman M., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379-2388.
27. Clinical Study Results Database Protocol number GAL-INT-11. Accessible on-line http://www.clinicalstudyresults.org/documents/ company-study_96_1.pdf.
28. Clinical Study Results Database Protocol number GAL-INT-18. Accessible on-line: http://www.clinicalstudyresults.org/documents/ company-study_96_2.pdf.
29. US Food and Drug Administration [FDA] (2005) Alert for healthcare professionals on galantamine hydrochloride (marketed as Reminyl). Rockville (Maryland): FDA. Accessible on-line: http://www.fda.gov/cder/ drug/InfoSheets/HCP/galantamineHCP.htm.
30. Feldman H., Ferris S., Mancione L., et al. The treatment of mild cognitive impairment with rivastigmine: results from the InDDEx study Abstracts of 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, Geneva, 19-22 April, 2006. Neurobiol Aging 2006; 27 (Suppl 1): S7.
31. Benavente O., Hart R., Koudstaal P., et al. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks (Cochrane Review). In: The Cochrane Library Issue 3, 2003. Oxford: Update Software.
32. Segal J.B., McNamara R.L., Miller MR., et al. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter (Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Oxford: Update Software.
33. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
34. Small B.J., Fratiglioni L., Viitanen M., et al. The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population-based sample. Arch Neurol 2000; 57: 839-844.
35. de Leon M.J., DeSanti S., Zinkowski R., et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 2006; 27: 394-401.
36. Sobow T., Flirski M., Kloszewska I., et al. Plasma levels of Aβ peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta Neurobiol Exp (Wars) 2005; 65: 117-124.
37. Modrego P.J. Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment. Curr Alzheimer Res 2006; 3: 161-170.